We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MolMed Signs an Agreement With GlaxoSmithKline to Develop a Production Process for a Gene Therapy
News

MolMed Signs an Agreement With GlaxoSmithKline to Develop a Production Process for a Gene Therapy

MolMed Signs an Agreement With GlaxoSmithKline to Develop a Production Process for a Gene Therapy
News

MolMed Signs an Agreement With GlaxoSmithKline to Develop a Production Process for a Gene Therapy

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MolMed Signs an Agreement With GlaxoSmithKline to Develop a Production Process for a Gene Therapy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MolMed S.p.A. has announced that it has signed an agreement with GlaxoSmithKline (GSK) under which MolMed will develop a production process for an investigational gene therapy for ADA-SCID (Adenosine Deaminase Deficiency - Severe Combined Immune Deficiency), a very rare and life-threatening disease that affects approximately 350 children worldwide.

Under the terms of the agreement, MolMed will receive up to EUR 5.5 million in revenues over a two-year period.

ADA-SCID is a disease caused by the alteration of a single gene; it was thus possible to develop a therapy by inserting, through gene transfer technology, the correct form of the gene into the patient's own stem cells derived from their bone marrow.

This gene therapy, which is in late stage clinical trials, has been developed by the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET) and was in-licensed by GSK to develop and commercialize the therapy.

Claudio Bordignon, chairman and CEO of MolMed, comments: "We are extremely pleased to have entered into this agreement with GSK. MolMed has expertise and know-how in the field of gene and cell therapy and this agreement with GSK is an important step on the way to provide gene therapy for patients with rare diseases. I am very proud that today MolMed can give its industrial contribution to this innovative and advanced field of medicine."

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14.5.1999, as subsequently amended.

Advertisement